Počet záznamů: 1  

Current progress in the therapeutic options for mitochondrial disorders

  1. 1.
    0536888 - FGÚ 2021 RIV CZ eng J - Článek v odborném periodiku
    Koňaříková, Eliška - Marković, Aleksandra - Korandová, Zuzana - Houštěk, Josef - Mráček, Tomáš
    Current progress in the therapeutic options for mitochondrial disorders.
    Physiological Research. Roč. 69, č. 6 (2020), s. 967-994. ISSN 0862-8408. E-ISSN 1802-9973
    Grant CEP: GA MZd(CZ) NV19-07-00149
    Institucionální podpora: RVO:67985823
    Klíčová slova: mitochondria * OXPHOS * mitochondrial diseases * gene therapy * mitochondrial donation
    Obor OECD: Human genetics
    Impakt faktor: 1.881, rok: 2020
    Způsob publikování: Open access
    https://www.biomed.cas.cz/physiolres/pdf/2020/69_967.pdf

    Mitochondrial disorders manifest enormous genetic and clinical heterogeneity - they can appear at any age, present with various phenotypes affecting any organ, and display any mode of inheritance. What mitochondrial diseases do have in common, is impairment of respiratory chain activity, which is responsible for more than 90 % of energy production within cells. While diagnostics of mitochondrial disorders has been accelerated by introducing Next-Generation Sequencing techniques in recent years, the treatment options are still very limited. For many patients only a supportive or symptomatic therapy is available at the moment. However, decades of basic and preclinical research have uncovered potential target points and numerous compounds or interventions are now subjects of clinical trials. In this review, we focus on current and emerging therapeutic approaches towards the treatment of mitochondrial disorders. We focus on small compounds, metabolic interference, such as endurance training or ketogenic diet and also on genomic approaches.
    Trvalý link: http://hdl.handle.net/11104/0314640

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.